$OCFN: Look out, a HUGE NEWS is going to hit the wires

New Post Public Reply Private Reply Replies (0) Message Board
Jack30
$OCFN: Look out, a HUGE NEWS is going to hit the wires soon. Raised more than 40mil with warrants of $1.42 per share. Now sitting at .02.

A $43-Million Record Amount of Investment Capital Negotiated by OCFN's Management

7:30 AM ET 11/19/13 | Marketwire

Omega Commercial Finance Corporation (OTCQB: OCFN), a publicly traded financial holding company, reports financial results led by a strengthened Balance Sheet for the third quarter and nine months ending September 30, 2013 and the receiving of a $40,643,208 cash investment to help garner its growth.

View data

-- First and foremost liquidity is a measure of a company's ability to meet potential cash requirements. On September 30, 2013 OCFN had total assets of $3,184,298 compared to $253,031 on December 31, 2012, which is an increase of $2,931,267 (1,158.54%). -- The increase was primarily attributable to $3,000,000 of restricted cash received and $160,000 in Other Assets, partially offset by an $88,043 reduction in cash. The cash that is identified as "restricted" is more defined as capital designated for M&A expansion for OCFN's lending operations and financial services. -- The $3-million cash investment was from a September 4th 2013 Direct Pubic Offering sale of 30 million common stock shares at a fixed price of $0.10 sold to three (3) private investors for the use as explained herein. -- OCFN reported total stockholders' equity of $559,993 on September 30, 2013 compared to the deficit of stockholders' equity of $2,255,663 on December 31, 2012, a reduction in the deficit of $2,815,656 -- OCFN reported a Common stock and Preferred stock offering of $40,643,208 completed and fully funded as of October 4, 2013 as a "Subsequent Event" that has been received into their restricted cash account. -- This $40,643,208 can be identified on the Balance Sheet and is classified as a "Preferred Receivable" that consisted of 900 Series A Preferred shares sold at $42,344 per share with Common Stock Warrants with an average price per share of $1.42. -- OCFN also reported on their 'Cash Flow from Operations' statement in the 'Other Non-Cash Financing Activities' an ending balance increase to $2,911,958

To summarize, OCFN reached a record high of $43,643,208 of investment capital, which is a key fundamental driver for any small cap growth company. Jon S. Cummings IV, states "I am ecstatic about this past quarter and glad to have negotiated $43-million in cash investments. More importantly, we thank all our colleagues who have supported us through this process and who believe and trust in our business model and growth initiatives. It's my job to prudently ensure that we continue this momentum forward."

A Recent Accomplishment

OCFN core lending subsidiary Omega Capital Street LLC signed a Sublease to expand its CMBS-style and bridge-lending operations in a 6,200sq./ft. office space by staffing proven CRE finance advisor's, originators, and a credit team . The move-in date is on January 1, 2014 at the 701 Bank of America Class A Office building on the prestigious Brickell Avenue located in the heart of Miami Florida's financial district said to be known as the "Wall Street of the South".

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 33

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 37

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 29

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 40

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 44

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading

Top 5 Most Recently Viewed Articles

Icon Energy Corp. Welcomes M/V Bravo and Secures Funding

Updated Category News Views 84

Icon Energy Corp. Welcomes M/V Bravo and Secures Financing Icon Energy Corp. (“Icon”) (Nasdaq: ICON) is thrilled to announce the arrival of its latest fleet member, the M/V Bravo, alongside significant financing aimed at facilitating future growth. This advanced Kamsarmax dry bulk carrier represents a key achievement in Icon's operational strategy, paving the way for...

Continue Reading
Kimbell Royalty Partners Delivers Strong Q3 2025 Financials

Updated Category News Views 122

Kimbell Royalty Partners Reports Impressive Third Quarter Financial Results Kimbell Royalty Partners, LP (NYSE: KRP), a prominent entity in the oil and natural gas sector, recently revealed its financial performance for the quarter concluding September 30, 2025. The company demonstrated strong operational results despite a challenging industry backdrop. Production and...

Continue Reading
Nscale and Microsoft Partner to Transform AI Infrastructure

Updated Category News Views 255

Nscale and Microsoft's Groundbreaking Partnership Nscale is embarking on an incredible journey with Microsoft, having signed a substantial contract to deploy nearly 200,000 NVIDIA GB300 GPUs. This collaboration aims to redefine AI infrastructure across Europe and the U.S., marking one of the largest agreements in the field of AI technology. Unveiling the Scope of the...

Continue Reading
Alterity Therapeutics Wraps Up Participant Visits in MSA Trial

Updated Category News Views 242

Alterity Therapeutics Wraps Up Patient Visits in Clinical Trial Alterity Therapeutics, recognized for its dedication to tackling neurodegenerative diseases, has reached a significant milestone by completing participant visits in the ATH434-201 Phase 2 clinical trial focusing on early-stage multiple system atrophy (MSA). This trial, which follows a randomized,...

Continue Reading
Huawei Launches Innovative Solutions for European SMEs' Growth

Updated Category News Views 193

Huawei Empowers European SMEs with Intelligent Solutions Huawei, a global leader in information and communications technology, has made significant strides in assisting small and medium-sized enterprises (SMEs) across Europe to embrace digital transformation. The company recently introduced its latest offerings at a major launch event, focusing on simplifying the path for...

Continue Reading